Since GLP-1s entered the spotlight in 2023 promising sustainable weight loss as high as 20%, they’ve sparked public interest like few drugs before them. 

Given how consumer driven weight management is, it’s critical for pharmaceutical companies to understand the motivations, behaviors and experiences of people who are trying to lose weight. While some consumers turn to GLP-1s and other medications to meet their weight management goals, far more currently use nonmedical interventions such as diet and lifestyle changes, fitness tracking and supplements.

Using Atlas Intelligence, ZS’s proprietary AI-powered consumer intelligence platform, the authors of this white paper take a holistic look at the weight management category to uncover key insights and opportunities for companies that operate in this space today or aspire to do so in the future.

Uncover consumer insights on GLP-1s